YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
The U.S. Food and Drug Administration on Monday cleared an experimental drug from Eli Lilly for people with mild or moderate COVID-19 symptoms not requiring hospitalization.
The antibody drug, called bamlanivimab, is similar to a treatment President Donald Trump received after contracting the virus last month. The government previously reached an agreement to buy and supply much of the early production of Lilly’s drug.
Officials say bamlanivimab requires additional testing to establish its safety and effectiveness.
Read more from The Associated Press.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Banker pleads guilty to fraud scheme
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Caterpillar to acquire John Fabick Tractor Co.
Eric Schmitt introduces Modern Skies Act
Springfield airport to cut the ribbon on $35M in construction projects